跳至主要内容
临床试验/NCT01136213
NCT01136213已完成不适用

Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study

University Hospital, Bordeaux5 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2010年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
53
试验地点
5
主要终点
18F-MPPF binding potential - Biding potential (BP) under placebo in the raphe nucleus

研究概览

简要总结

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder of the adult associated to a poor prognosis. MSA is clinically characterized by the association of extra-pyramidal, dysautonomic, cerebellar and pyramidal symptoms. Histological and biological studies have raised the hypothesis that, beside the well known dopamine deficiency, some of the symptoms could be related to a dysfunction in serotoninergic neurotransmission. Serotonin is involved in the modulation of several functions impaired in MSA, such as mood, motricity or sleep. The recent description of an association between loss of brainstem serotonin neurons and sudden death in patients with MSA reinforced the hypothesis of a critical role played by this neurotransmitter in the pathophysiology of this disease. Autoreceptors called 5-HT1a are strongly involved in the regulation of serotonin neurotransmission. During the last years several radio-ligands allowing in vivo PET quantification of 5-HT1a receptors, such as 18F-MPPF (4-(2'-methoxyphenyl)-1-[2'-(N-2''-piridinyl)-p-fluorobenzamide]methylpiperazine), were developed. Moreover, the investigators recently demonstrated the ability of this brain functional imaging method to investigate, in healthy volunteers, the functional properties of 5-HT1a autoreceptors through an evaluation of their desensitization after a single oral dose of fluoxetine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Health Services Research
盲法
Double (Participant, Investigator)

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with Multiple system atrophy (MSA)
  • MSA possible or probable
  • Male and female
  • Age : 30 to 80
  • No cognitive impairment
  • Unmodified treatment for 2 months
  • Able to give informed consent
  • Affiliated to social insurance
  • Patients with idiopathic Parkinson's disease (IPD):
  • Positive clinical criteria for IPD
  • Male and female
  • Age : 30 to 80
  • No cognitive impairment
  • Unmodified treatment for 2 months
  • Able to give informed consent
  • Affiliated to social insurance
  • Healthy controls:
  • Absence of neuropsychiatric disorder
  • Male and female
  • Age : 30 to 80
  • Able to give informed consent
  • Affiliated to social insurance

排除标准

  • Patients with Multiple system atrophy (MSA)
  • Other Parkinsonian syndrome
  • Recent intake (< 4 weeks or 8 weeks for fluoxetine) of medication acting on 5-HT1a receptors
  • History of major depression
  • Contraindication to brain MRI
  • Contraindication to PET
  • Patients with idiopathic Parkinson's disease
  • Other Parkinsonian syndrome
  • Recent intake (< 4 weeks or 8 weeks for fluoxetine) of medication acting on 5-HT1a receptors
  • History of major depression
  • Contraindication to brain MRI
  • Contraindication to PET
  • Healthy controls:
  • Patient having a neuropsychiatric disease
  • Recent intake (< 4 weeks or 8 weeks for fluoxetine) of medication acting on 5-HT1a receptors
  • History of major depression
  • Contraindication to brain MRI
  • Contraindication to PET

研究组 & 干预措施

Multiple system atrophy

干预措施: Fluoxétine / Placebo (Drug)

Multiple system atrophy

Active Comparator

干预措施: Brain MRI (magnetic resonance imaging) (Other)

Multiple system atrophy

Active Comparator

干预措施: PET (Positron Emission Tomography) Study (Radiation)

Volunteers without neuropsychiatric disorder (Control)

Active Comparator

干预措施: PET (Positron Emission Tomography) Study (Radiation)

Volunteers without neuropsychiatric disorder (Control)

Active Comparator

干预措施: Brain MRI (magnetic resonance imaging) (Other)

Volunteers without neuropsychiatric disorder (Control)

干预措施: Fluoxétine / Placebo (Drug)

Idiopathic Parkinson Disease

干预措施: Fluoxétine / Placebo (Drug)

Idiopathic Parkinson Disease

Placebo Comparator

干预措施: Brain MRI (magnetic resonance imaging) (Other)

Idiopathic Parkinson Disease

Placebo Comparator

干预措施: PET (Positron Emission Tomography) Study (Radiation)

结局指标

主要结局

18F-MPPF binding potential - Biding potential (BP) under placebo in the raphe nucleus

时间窗: Second visit (day 1)

Amount of 5-HT1a autoreceptors (evaluated by measurement of 18F-MPPF binding potential) after intake of placebo in the raphe nucleus.

次要结局

  • Clinical parameters (motor handicap, orthostatic hypotension, quality of life, sleep, pain, tiredness)(Third visit (day 30))
  • 18F-MPPF binding potential - Biding potential (BP) under placebo in other brain areas(Third visit (day 30))
  • 18F-MPPF binding potential - Biding potential (BP) in other brain areas(Second visit (day 1))
  • 18F-MPPF binding potential - BP under fluoxetine in all brain areas(Third visit (day 30))

研究者

发起方
University Hospital, Bordeaux
申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验

Investigation of the Serotoninergic System in... | 临床试验